KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Share-based Compensation (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Share-based Compensation readings, the most recent being $43.0 million for Q1 2026.

  • On a quarterly basis, Share-based Compensation rose 26.47% to $43.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $166.0 million, a 28.68% increase, with the full-year FY2025 number at $157.0 million, up 27.64% from a year prior.
  • Share-based Compensation hit $43.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $51.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $51.0 million in Q4 2025 to a low of $24.0 million in Q1 2022.
  • Median Share-based Compensation over the past 5 years was $32.0 million (2023), compared with a mean of $33.5 million.
  • Biggest five-year swings in Share-based Compensation: decreased 23.08% in 2023 and later soared 50.0% in 2025.
  • Teva Pharmaceutical Industries' Share-based Compensation stood at $36.0 million in 2022, then dropped by 22.22% to $28.0 million in 2023, then increased by 21.43% to $34.0 million in 2024, then soared by 50.0% to $51.0 million in 2025, then fell by 15.69% to $43.0 million in 2026.
  • The last three reported values for Share-based Compensation were $43.0 million (Q1 2026), $51.0 million (Q4 2025), and $34.0 million (Q3 2025) per Business Quant data.